（吉隆坡18日讯）卫生总监丹斯里诺希山指出，根据最大的临床试验，抗寄生虫药物伊维菌素（Ivermectin）并没有减少新冠肺炎入院率。
他今晚在推特张贴一段临床研究机构（ICR）的视频，重申伊维菌素只应用作临床试验。
Ivermectin didnt reduce Covid-19 hospitalisations in Largest Trial to date.
Patients who got the antiparasitic drug didn’t fare better than those who received a placebo. pic.twitter.com/yJwldDa5OG— Noor Hisham Abdullah (@DGHisham) March 18, 2022
